Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

15/433 Matches for
“direct-acting antivirals”

“direct-acting antivirals” Clear all

  1. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

    Asselah T et al. · Liver Int · 2018 Match 100

    ### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…

    FibroTest HCV

  2. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 97

    …CHC) treated or not with antivirals. ### Methods Pre-included patients were from…

    LCR1 LCR2 HCV

  3. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 94

    Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…

    ActiTest FibroTest HCV

  4. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 90

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  5. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 87

    …after adjustment for exposure to antivirals, age, gender, geographical origin, HBe-Ag…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  6. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 84

    ActiTest FibroTest HBV

  7. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 80

    ActiTest FibroTest HCV

  8. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

    Haseltine EL et al. · J Viral Hepat · 2015 Match 77

    Patients infected with hepatitis C virus (HCV) have differing levels of liver…

    FibroTest HCV

  9. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.

    Steininger K et al. · J Viral Hepat · 2017 Match 74

    …New direct-acting antiviral agent (DAA) combination therapy has not yet been…

    FibroTest HCV HIV

  10. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 70

    ### Background Direct antiviral agents (DAA) showed very good results in terms of…

    FibroTest HCV

  11. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 67

    ActiTest FibroTest HCV

  12. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 64

    FibroTest HCV

  13. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 60

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  14. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 57

    FibroTest HBV

  15. Ministère des Affaires Sociales et de la Santé Key publication

    Match 54

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.